Editor Note: For more information about this release, please scroll to bottom.
LONDON, May 6, 2014 /PRNewswire/ --
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ:PDLI), Cytokinetics Inc. (NASDAQ:CYTK), Vical Inc. (NASDAQ:VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
On Monday, shares in PDL BioPharma Inc. fluctuated between $8.32 and $8.45 before ending the session 0.35% lower at $8.43. PDL BioPharma Inc.'s stock reported a trading volume of 2.01 million shares, much below its three months average volume of 3.40 million shares. Shares of the company traded at a PE ratio of 4.87. Over the last one month and over the previous three months, PDL BioPharma Inc.'s shares have gained 4.59% and 13.00% respectively. However, from the beginning of 2014, the company's stock has declined 0.12%. The stock is trading above its 50-day and 200-day moving averages of $8.38 and $8.36, respectively. Moreover, shares of the company have a Relative Strength Index (RSI) of 53.49. Sign up today to read free research on PDLI at:
On Monday, Cytokinetics Inc.'s stock edged 0.22% higher, to close the day at $4.47. The stock recorded a trading volume of 1.08 million shares, much below its three months average volume of 1.48 million shares. The stock oscillated between $4.34 and $4.53 during the session. Cytokinetics Inc. shares have plummeted 1.76% in the previous three trading sessions, 34.74% in the last three months and 31.23% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Further, the stocks 50-day moving average of $9.23 is above its 200-day moving average of $8.48. Additionally, the stock has an RSI of 31.70. Sign up today to read free research on CYTK at:
Vical Inc.'s stock finished the Monday's session 0.87% higher at $1.16. A total of 0.56 million shares were traded, which was below its three months average volume of 1.24 million shares. The stock moved between $1.11 and $1.16 during the session. Vical Inc.'s share gained 2.65% in the previous three trading sessions. However, from the beginning of 2014, the company's stock has declined 1.69%. The company's shares are trading below their 50-day and 200-day moving averages. Additionally, the stock's 200-day moving average of $1.50 is greater than its 50-day moving average of $1.33. Vical Inc.'s stock has an RSI of 42.95. Sign up today to read free research on VICL at:
On Monday, shares in Peregrine Pharmaceuticals Inc. recorded a trading volume of 0.90 million shares, much lower than its three months average volume of 3.94 million shares. The stock ended the day at $1.84, which was 2.13% below its previous day's closing of $1.88, and registered an intraday range of $1.81 and $1.90. Peregrine Pharmaceuticals Inc.'s shares have advanced 5.75% in the previous three trading sessions and 9.52% in the last three months. Additionally, from the beginning of 2014, the company's stock has gained an upside of 32.37%. The company's stock is trading above its 200-day moving average of $1.58. Furthermore, shares of the company have an RSI of 51.84. Sign up today to read free research on PPHM at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.